Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Randomized, Controlled Study of Equecabtagene Autoleucel Injection in Subjects With Lenalidomide-Refractory R/R Multiple Myeloma

NCT06464991 is registered in ClinicalTrials.gov with Nanjing IASO Biotechnology Co., Ltd. as lead sponsor.

NCT NCT06464991
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06464991 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Randomized, Controlled Study of Equecabtagene Autoleucel Injection in Subjects With Lenalidomide-Refractory R/R Multiple Myeloma
Lead sponsor
Nanjing IASO Biotechnology Co., Ltd.
Phase
Phase 3
Overall status
Recruiting
Start date
March 27, 2024
Completion date
December 31, 2030
Enrollment
240 (estimated)
Sites
28

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma